Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

BioScience Trends

Volumn 14, Issue 1, 2020, Pages

  Wang, Zhenwei ^a   Chen, Xiaorong ^b   Lu, Yunfei ^b   Chen, Feifei ^c   Zhang, Wei ^c  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^c SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

2019 nCoV; Arbidol; Lopinavir; Ritonavir; Shufeng Jiedu Capsule

Indexed keywords

ANTIVIRUS AGENT; ARBIDOL; COVID-19; HERBACEOUS AGENT; INDOLE DERIVATIVE; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; RITONAVIR; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SHUFENG JIEDU;

ADULT; BETACORONAVIRUS; CASE REPORT; CHINA; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; DRUG COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS PNEUMONIA; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; BETACORONAVIRUS; CHINA; CORONAVIRUS INFECTIONS; DRUG COMBINATIONS; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; INDOLES; LOPINAVIR; MALE; MIDDLE AGED; PNEUMONIA, VIRAL; RETROSPECTIVE STUDIES; RITONAVIR; YOUNG ADULT;

EID: 85080854126     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/BST.2020.01030     Document Type: Article

References (11)

1. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020; 12. doi: 10.3390/v12020135.
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020. doi: 10.1056/NEJMoa2001017.
3. Notification of 2019-nCoV infection. National Health Commission of the People's Republic of China. http://www.nhc.gov.cn/xcs/yqtb/202002/17a03704a99646ffad6807bc806f37a4.shtml (accessed February 5, 2019). (in Chinese)
4. Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (version 5). http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml (accessed February 5, 2020). (in Chinese)
5. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020. doi: 10.5582/bst.2020.01020.
6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020. doi: 10.1016/S0140-6736(20)30183-5.
7. Su B, Wang Y, Zhou R, Jiang T, Zhang H, Li Z, Liu A, Shao Y, Hua W, Zhang T, Wu H, He S, Dai L, Sun L. Efficacy and tolerability of lopinavir/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front Pharmacol. 2019; 10:1472.
8. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, Peiris JS, Yuen KY, Group HUSS. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59:252-256.
9. Wang Y, Ding Y, Yang C, Li R, Du Q, Hao Y, Li Z, Jiang H, Zhao J, Chen Q, Yang Z, He Z. Inhibition of the infectivity and inflammatory response of influenza virus by arbidol hydrochloride in vitro and in vivo (mice and ferret). Biomed Pharmacother. 2017; 91:393-401.
10. News. http://www.sd.chinanews.com/2/2020/0205/70145.html (accessed February 5, 2020). (in Chinese)
11. Chinese Clinical Trial Registry. http://www.chictr.org.cn/showproj.aspx?proj=49065 (accessed February 5, 2019).